{
  "id": "420da3e33bb7fdca",
  "title": "Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti - PD - 1 Antibody Serplulimab in Japan",
  "description": "20260206T111500Z",
  "content": "",
  "source": "jcnnewswire.com",
  "source_url": "https://www.jcnnewswire.com/pressrelease/105035/3/Eisai-and-Henlius-Enter-into-Exclusive-Commercial-License-Agreement-for-Anti-PD-1-Antibody-Serplulim",
  "published_at": "20260206T111500Z",
  "fetched_at": "2026-02-07T00:27:41.919994+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai"
  ],
  "location": "Japan",
  "raw_data": {
    "url": "https://www.jcnnewswire.com/pressrelease/105035/3/Eisai-and-Henlius-Enter-into-Exclusive-Commercial-License-Agreement-for-Anti-PD-1-Antibody-Serplulim",
    "url_mobile": "",
    "title": "Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti - PD - 1 Antibody Serplulimab in Japan",
    "seendate": "20260206T111500Z",
    "socialimage": "",
    "domain": "jcnnewswire.com",
    "language": "English",
    "sourcecountry": "Japan"
  }
}